Atossa Therapeutics, Inc. ATOS 深 沪
等待开盘 04-02 09:30:00 美东时间
5.11
-0.150
-2.85%
华盛通- 最 高5.36
- 今 开5.27
- 成交量 6.33万股
- 最 低 5.03
- 昨 收 5.26
- 总市值 4400.41万
- 52周最高 19.35
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 3.76
- 委 比 98.96%
- 总股本 861.14万
- 历史最高 33480.00
- 量 比 0.79
- 振 幅 6.27%
- 历史最低 5.03
- 每 手 1
- 风险率 3.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.
03-26 20:08
Atossa Therapeutics Q4 EPS $(0.03) Beats $(0.07) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 55.22 percent. This is a 88 percent increase over losses of $(0.25) per share from
03-26 05:44
Atossa Therapeutics Presents Oral Clinical Update On (Z)-endoxifen At MDA Clinical & Scientific Conference
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need,
03-12 20:12
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
The latest update is out from Atossa Therapeutics ( ($ATOS) ). On February 17, ...
02-18 07:12
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
Atossa Therapeutics ( ($ATOS) ) has shared an update. On February 11, 2026, Ato...
02-11 22:23
Atossa Therapeutics Completes Reverse Stock Split
Atossa Therapeutics Completes Reverse Stock Split Atossa Therapeutics Inc. has completed a reverse stock split, effective February 2, 2026. The move is intended to help the company regain compliance with Nasdaq listing requirements. Disclaimer: This news brief was created by Public Technologies (PUB
02-11 21:31
Atossa Therapeutics Passes Five-Year Reauthorization Of Rare Pediatric Disease Priority Review Voucher Program
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today reaffirmed its
02-05 21:41
Atossa Therapeutics Announces 15-for-1 Reverse Stock Split
Atossa Therapeutics Announces 15-for-1 Reverse Stock Split Atossa Therapeutics Inc. has announced a 15-for-1 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on February 2, 2026. The company's shares will begin trading on a split-adjusted basis under a new CUSIP number,
01-26 21:02
